VYCO · XBRL financial data

Vycor Medical financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (VYCO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	1,142	1,393	1,223	1,461	1,589	1,863
Cost of goods and services sold	132	135	141	145	167	302
Gross profit	1,010	1,258	1,082	1,316	1,423	1,561
Research and development	0	15	—	23	15	10
Selling, general and administrative	1,680	1,613	1,331	1,195	1,357	1,458
Total operating expenses	1,737	1,694	1,389	1,275	1,432	1,527
Operating income (loss)	(727)	(436)	(307)	40	(9)	34
Net income (loss)	(822)	(436)	(405)	(70)	(107)	(72)
Earnings per share, basic USD per share	—	(0.03)	(0.02)	(0.01)	(0.01)	(0.01)
Earnings per share, diluted USD per share	—	—	(0.02)	(0.01)	(0.01)	(0.01)
Weighted average shares, basic thousands of shares	—	29,628	31,708	32,604	32,885	33,373
Weighted average shares, diluted thousands of shares	—	—	31,708	32,604	32,885	33,373

Fiscal years (VYCO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	46	91	37	57	106	87
Accounts receivable	159	126	156	215	245	219
Inventory	181	208	249	234	222	159
Prepaid and other current assets	77	62	74	77	122	97
Total current assets	464	487	518	584	696	563
Property and equipment, net	381	362	304	252	193	134
Right-of-use asset	124	80	33	150	104	55
Total assets	987	935	860	992	998	830
Accounts payable	179	228	200	118	148	85
Accrued liabilities	—	—	—	—	158	90
Total current liabilities	2,741	3,150	3,655	4,074	4,497	4,781
Long-term debt	150	150	—	—	—	—
Lease liability, non-current	77	31	—	100	52	—
Total liabilities	2,968	3,331	3,801	4,318	4,688	4,917
Accumulated deficit	(30,937)	(31,697)	(32,426)	(32,820)	(33,252)	(33,649)
Total stockholders' equity	(1,981)	(2,395)	(2,941)	(3,325)	(3,690)	(4,087)
Total liabilities and equity	987	935	860	992	998	830
Common shares outstanding (cover page) thousands of shares	27,898	31,456	32,629	32,629	33,373	33,373

Fiscal years (VYCO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(822)	(436)	(405)	(70)	(107)	(72)
Stock-based compensation	520	341	186	10	27	49
Net cash from operating activities	(249)	21	(217)	29	60	(13)
Purchases of property and equipment	62	38	3	9	4	5
Net cash from investing activities	(52)	(38)	(3)	(9)	(4)	(4)
Net cash from financing activities	287	62	166	0	(8)	(1)
Net change in cash	(15)	45	(54)	20	48	(19)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Vycor Medical	159	418	(4.8)*	33.4M	32.8 quarters	Q2 FY26 10-QJun 30, 2026
NutriBand	3,422	438	(585)*	12.2M	—	Q2 FY27 10-QJul 31, 2026
QHSLab	317	847	(7.8)*	15.0M	40.6 quarters	Q2 FY26 10-QJun 30, 2026
Premier Air Charter Holdings	157	5,784	318*	280.8M	—	Q2 FY26 10-QJun 30, 2026
INVO Fertility	3,733	2,175	(1,101)*	2.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Profusa	719	not reported	(2,632)*	605,647	0.3 quarters	Q2 FY26 10-QJun 30, 2026
LogicMark	3,496	3,349	83*	899,759	—	Q2 FY26 10-QJun 30, 2026
Stimcell Energetics	6.9	not reported	(109)	21.1M	0.1 quarters	Q1 FY27 10-QAug 31, 2026
Bluejay Diagnostics	9,599	not reported	(1,499)*	4.5M	6.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.